- English (USA)
- English (UK)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Galderma Group AG (GALD)
The Galderma share price today is 176.00, view SIX GALD stock exchange data. Track the latest Galderma share price with real-time updates on GALD stock performance including market cap, day range, 52-week range and dividend yield. Access GALD charts, earnings dates and analyst estimates to support your investment decisions.
Currency in CHF
176.00
+0.10(+0.06%)
Closed·
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
174.50
177.50
52 wk Range
129.90
188.25
GALD is included in our AI-picked strategies. See how they work
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
174.50177.50
52 wk Range
129.90188.25
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
(0.20%)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Book Value / Share
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
(0.20%)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Book Value / Share
GALD Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Neutral
Price Target
194.22
Upside
+10.35%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Trading at a low P/E ratio relative to near-term earnings growth
Galderma receives Investment Bank Analyst Rating Update- Investing.com
Pro
Galderma receives Investment Bank Analyst Rating Update- Investing.com
Pro
Galderma receives Investment Bank Analyst Rating Update- Investing.com
Pro
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Strong Sell
Analyst Ratings
15 Buy
2 Hold
1 Sell
Ratings:
18 analysts
Overall Consensus
Buy
Analysts 12-Month Price Target:
Average 194.22
(+10.35% Upside)
Galderma Group AG Earnings Call Summary for Q2/2026
- Galderma reported record H1 2026 sales of $3.1B, up 24.6% at constant currency; raised FY guidance to 19-21% growth from prior outlook.
- Core EBITDA surged 42.8% YoY to $802M with margin expanding to 25.6%; reported EPS of $0.254 missed $1.27 estimate by 80% despite revenue beat.
- Nemluvio drove U.S. sales up 32.3%, on track to exceed $1B annually; FDA issued Complete Response Letter delaying Relfydess launch timeline.
- Net leverage improved to 1.2x EBITDA from 1.5x; company returned $406M to shareholders via dividends and buybacks in first half.
- Shares fell 1.55% to $171.35 on earnings miss concerns; management confirmed 26% core EBITDA margin target and plans FDA meeting in autumn.
Last Updated: 23-07-2026, 05:36 pm
Read Full TranscriptEarnings
Latest Release
23-07-2026
EPS / Forecast
1.27 / 1.27
Revenue / Forecast
1.66B / 1.57B
Compare GALD to Peers and Sector
Metrics to compare | GALD | Sector Sector - Average of metrics from a broad group of related Consumer Non-Cyclicals sector companies | Relationship RelationshipGALDPeersSector | |
|---|---|---|---|---|
P/E Ratio | 58.4x | 23.8x | −0.3x | |
PEG Ratio | 0.45 | −0.05 | 0.00 | |
Price/Book | 6.1x | 4.0x | 2.6x | |
Price / LTM Sales | 8.5x | 4.9x | 3.1x | |
Upside (Analyst Target) | 12.6% | 7.1% | 48.3% | |
Fair Value Upside | Unlock | 9.5% | 6.7% | Unlock |
Galderma Group AG operates as a dermatology company worldwide. The company delivers a science-based portfolio of brands and services for the dermatology market, including injectable aesthetics, dermatological skincare, and therapeutic dermatology. Its portfolio of flagship brands includes Azzalure, ALLUZIENCE, Dysport, Restylane, Restylane Skinboosters, Sculptra, Cetaphil, ALASTIN, Soolantra, Epiduo, Epiduo Forte, Differin, AKLIEF, Oracea, Metvix, NEMLUVIO, Relfydess, Benzac, and Loceryl in therapeutic dermatology. The company was founded in 1981 and is headquartered in Zug, Switzerland.
Ownership
Ownership Overview
Top Holders
FAQ
What Is the Galderma (GALD) Share Price Today?
The Galderma share price today is 176.00.
What is the current Galderma (GALD) share price and day range?
As of 13-08-2026, the Galderma share price is 176.00, with a previous close of 176.00. The share price has ranged from 174.50 to 177.50 today, while the 52-week range spans from 129.90 to 188.25.
What Is the Galderma Market Cap?
As of today, Galderma market cap is 41.04B.
Does Galderma Pay Dividends? What's The Current Dividend Yield?
The Galderma dividend yield is 0.2%.
What Is the Galderma (GALD) Share Price Target?
The average 12-month share price target for Galderma is 194.22, with a high estimate of 261.33153224 and a low estimate of 129.24424111. 15 analysts recommend buying, while 1 suggest selling, with an overall rating of Buy and +10.35% Upside potential.
What Is Galderma's Earnings Per Share (TTM)?
The Galderma EPS (TTM) is 3.65.
When Is the Next Galderma Earnings Date?
Galderma will release its next earnings report on 22-10-2026.
From a Technical Analysis Perspective, Is GALD a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Neutral.
What Stock Exchange Does Galderma Trade On?
Galderma is listed and trades on the Switzerland Stock Exchange.
What Is the Stock Symbol for Galderma?
The stock symbol for Galderma is "GALD."
How Many Times Has Galderma Stock Split?
Galderma has split 0 times.
How Many Employees Does Galderma Have?
Galderma has 7676 employees.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.